Buy & Sell Prudential PLC (PUK) – Prudential PLC Price Today
Aura AI Summary
Key Stats
- $38.88BMarket Cap
- FinancialsSector
- -12.61%3M Drawdown
- $40.32BEnterprise Value
- 1.7%Dividend Yield
- 2% Buy | 98% SellTrading Activity
- 119 daysTypical Hold Time
Prudential PLC (PUK) is currently valued at a market capitalization of $38.88B, with an enterprise value of $40.32B. Over the past 52 weeks, Prudential PLC has traded between a low of $22.44 and a high of $33.61, highlighting its annual price range. Over the past three months, Prudential PLC has recorded a drawdown of -12.61%, reflecting recent price volatility. Prudential PLC offers a dividend yield of 1.7%, with the most recent dividend of $0.38 paid on 27 Mar 26. On average, investors hold Prudential PLC for approximately 119 days, indicating typical investor behavior on the platform.
About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Most Recent News
Investor Ron Baron predicts SpaceX could reach $30 trillion valuation and plans to buy $1B more shares at IPO.
Ron Baron, CEO of Baron Capital, believes SpaceX could become the largest company globally, potentially reaching a valuation of $10 to $30 trillion in the next 10 to 15 years. He has already invested $15 billion in SpaceX, which is the largest holdin...
Swatch Group shares rise 29% YTD, outperforming luxury sector amid market recovery hopes
The Swatch Group AG's stock has surged 29% year-to-date, reaching one-year highs and outperforming the S&P Global Luxury Index, which fell 9%. This rise reflects early signs of recovery in the luxury sector, supported by increased revenues in Asia ex...
Ascentage Pharma to showcase 17 clinical advances at 2026 European Hematology Association Congress
Ascentage Pharma announced it will present 17 clinical advances, including 8 poster presentations, at the 31st European Hematology Association Congress in June 2026. Highlights include data on Olverembatinib, China's first approved third-generation B...